Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Curtin

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Expert Opinion on Therapeutic Targets|May 17, 2007
Therapeutic potential of drugs to modulate DNA repair in cancerNicola Curtin
Biochemical Society Transactions|January 24, 2014
PARP inhibitors for anticancer therapyNicola Curtin
Cultural Diversity & Ethnic Minority Psychology|March 7, 2017
Not your model minority: Own-group activism among Asian AmericansJulia Tran, Nicola Curtin
Cancers|December 1, 2020
PARPs, PAR and NAD Metabolism and Their Inhibitors in CancerNicola Curtin, Péter Bai
Social Science Research|March 15, 2016
The differential impact of discrimination on health among Black and White womenH Shellae Versey, Nicola Curtin
Methods in Molecular Biology (Clifton, N.J.)|August 27, 2011
Strategies employed for the development of PARP inhibitorsStacie Canan, Karen Maegley, Nicola Curtin
Journal of Personality|June 25, 2010
What makes the political personal? Openness, personal political salience, and activismNicola Curtin, Abigail J Stewart, Lauren E Duncan
Pharmacology & Therapeutics|December 15, 2019
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?Alice Bradbury, Sally Hall, Nicola Curtin, et al.
Oncotarget|October 21, 2017
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancerMaryam Zanjirband, Nicola Curtin, Richard J Edmondson, et al.
Europe'S Journal of Psychology|March 25, 2022
The Importance of Awareness, Acceptance, and Alignment With the Self: A Framework for Understanding Self-ConnectionKristine Klussman, Nicola Curtin, Julia Langer, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Expert Opinion on Therapeutic Targets|May 17, 2007
Therapeutic potential of drugs to modulate DNA repair in cancerNicola Curtin
Biochemical Society Transactions|January 24, 2014
PARP inhibitors for anticancer therapyNicola Curtin
Cultural Diversity & Ethnic Minority Psychology|March 7, 2017
Not your model minority: Own-group activism among Asian AmericansJulia Tran, Nicola Curtin
Cancers|December 1, 2020
PARPs, PAR and NAD Metabolism and Their Inhibitors in CancerNicola Curtin, Péter Bai
Social Science Research|March 15, 2016
The differential impact of discrimination on health among Black and White womenH Shellae Versey, Nicola Curtin
Methods in Molecular Biology (Clifton, N.J.)|August 27, 2011
Strategies employed for the development of PARP inhibitorsStacie Canan, Karen Maegley, Nicola Curtin
Journal of Personality|June 25, 2010
What makes the political personal? Openness, personal political salience, and activismNicola Curtin, Abigail J Stewart, Lauren E Duncan
Pharmacology & Therapeutics|December 15, 2019
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?Alice Bradbury, Sally Hall, Nicola Curtin, et al.
Oncotarget|October 21, 2017
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancerMaryam Zanjirband, Nicola Curtin, Richard J Edmondson, et al.
Europe'S Journal of Psychology|March 25, 2022
The Importance of Awareness, Acceptance, and Alignment With the Self: A Framework for Understanding Self-ConnectionKristine Klussman, Nicola Curtin, Julia Langer, et al.
Pageof 3